Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00985660 · ClinicalTrials.gov registry record · Phase 1
Bioequivalence Study of Nisoldipine Extended-Release Tablets, 30 mg
A Phase 1 study, sponsored by Mylan Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 78
- Enrollment target
NCT00985660: Completed Phase 1 study, sponsored by Mylan Pharmaceuticals.
NCT00985660 is a Phase 1 study that has completed, run by Mylan Pharmaceuticals. The registered enrollment target is 78 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (30% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00985660, a Phase 1 study, has completed, sponsored by Mylan Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 78 participants
- Enrollment target
Study Summary
The objective of this study was to investigate the bioequivalence of nisoldipine extended-release 30 mg tablets (by Mylan Pharmaceuticals Inc.) with Sular® Extended-Release 30 mg tablet (manufactured for First Horizon) following a single, oral 30 mg (1 × 30 mg tablet) dose administration in healthy adult subjects under fasting conditions.
Interventions
- DRUG Nisoldipine Extended-release Tablets, 30 mg
- DRUG Sular® Extended Release Tablets, 30 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2007-06 |
| Est. Completion | 2007-07 |
| Phase | Phase 1 |
What the finished NCT00985660 record still lists
NCT00985660 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (30% higher).
The record links to 0 conditions, and to 2 interventions - of which Nisoldipine Extended-release Tablets, 30 mg is the first listed.
NCT00985660 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00985660 about?
NCT00985660 is a clinical study titled "Bioequivalence Study of Nisoldipine Extended-Release Tablets, 30 mg". The objective of this study was to investigate the bioequivalence of nisoldipine extended-release 30 mg tablets (by Mylan Pharmaceuticals Inc.) with Sular® Extended-Release 30 mg tablet (manufactured for First Horizon) following a single, oral 30 mg (1 × 30 mg tablet) dose administration in healthy ...
What is the current status of trial NCT00985660?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2007-06. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00985660?
The interventions under investigation include: Nisoldipine Extended-release Tablets, 30 mg (DRUG), Sular® Extended Release Tablets, 30 mg (DRUG).
Who is sponsoring clinical trial NCT00985660?
This trial is sponsored by Mylan Pharmaceuticals, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00985660's enrollment target sits among peer trials
78 697th of 2000 higher than 1,298 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia